Influence of quitting smoking on diabetes-related complications: A scoping review with a systematic search strategy.

Cardiovascular disease Diabetes Diabetic foot Erectile dysfunction Nephropathy Neuropathy Retinopathy Smoking Smoking cessation

Journal

Diabetes & metabolic syndrome
ISSN: 1878-0334
Titre abrégé: Diabetes Metab Syndr
Pays: Netherlands
ID NLM: 101462250

Informations de publication

Date de publication:
22 May 2024
Historique:
received: 21 03 2024
revised: 13 05 2024
accepted: 17 05 2024
medline: 30 5 2024
pubmed: 30 5 2024
entrez: 29 5 2024
Statut: aheadofprint

Résumé

Smoking in people with diabetes markedly elevates their risk of developing complications and increases the likelihood of cardiovascular mortality. This review is the first to specifically provide evidence-based analysis about the influence of quitting smoking on diabetes-related complications in people with type 2 diabetes. The present review was carried out according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Extension for Scoping Reviews. All human clinical studies assessing the effects of stopping smoking cessation on diabetes-related complications were included. PubMed and Embase were screened until January 2024. References of primary studies and principal peer-reviewed scientific journals in the field were manually screened. We identified a total of 1023 studies. Only 26 met the criteria for eligibility. In general quitting smoking is associated with decreased risks of myocardial infarction and ischemic stroke. Regarding microvascular complications, the strongest evidence for the beneficial effects of smoking cessation is observed in diabetic nephropathy. However, the relationship between smoking cessation and retinopathy, neuropathy, diabetic foot complications and diabetic-related erectile dysfunction, is poorly investigated. Quitting smoking offers significant advantages in managing diabetes-related complications, significantly lowering the risks of myocardial infarction, ischemic stroke, and diabetic nephropathy. This underscores the importance of cessation. Providing evidence-based information on the benefits of stopping smoking for people with type 2 diabetes who smoke, can bolster smoking cessation efforts in the context of diabetes management.

Identifiants

pubmed: 38810420
pii: S1871-4021(24)00105-X
doi: 10.1016/j.dsx.2024.103044
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

103044

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Magdalena Walicka reports a relationship with Sanofi that includes: speaking and lecture fees and travel reimbursement. Magdalena Walicka reports a relationship with AstraZeneca that includes: speaking and lecture fees. Magdalena Walicka reports a relationship with Novo Nordisk that includes: travel reimbursement. Magdalena Walicka reports a relationship with Berlin-Chemie that includes: travel reimbursement. Arkadiusz Krysinski reports a relationship with Eclat SRL that includes: funding grants. Arkadiusz Krysinski reports a relationship with Berlin-Chemie that includes: travel reimbursement. Giusy Rita Maria La Rosa reports a relationship with ECLAT SRL that includes: funding grants. Ang Sun reports a relationship with ECLAT SRL that includes: travel reimbursement. Ang Sun reports a relationship with University of Catania that includes: travel reimbursement. Ang Sun reports a relationship with Sbarro Institute of Health that includes: non-financial support. Riccardo Polosa reports a relationship with Elsevier, EDRA, Pfizer, Boehringer Ingelheim, Duska Therapeutics, Forest Laboratories, CV Therapeutics, Sermo Inc., GRG Health, Clarivate Analytics, Guidepoint Expert Network, and GLG Group. That includes: consulting or advisory. Riccardo Polosa reports a relationship with European Technical Committee for Standardization that includes: board membership. Riccardo Polosa reports a relationship with Center for Tobacco Prevention and Treatment (CPCT) that includes: board membership. Riccardo Polosa reports a relationship with Foundation for a Smoke-Free World, Pfizer, GlaxoSmithKline, CV Therapeutics, Sandoz, Merk Sharp & Dohme, Boehringer Ingelheim, Novartis, Arbi Group Srl., Duska Therapeutics, and Forest Laboratories that includes: funding grants. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Magdalena Walicka (M)

Department of Human Epigenetics, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland; Department of Internal Diseases, Endocrinology and Diabetology, National Medical Institute of the Ministry of the Interior and Administration, Warsaw, Poland. Electronic address: magdalena.walicka@cskmswia.gov.pl.

Arkadiusz Krysiński (A)

Department of Human Epigenetics, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland; Department of Internal Diseases, Endocrinology and Diabetology, National Medical Institute of the Ministry of the Interior and Administration, Warsaw, Poland.

Giusy Rita Maria La Rosa (GR)

Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.

Ang Sun (A)

Department of Biology, and Center for Biotechnology/Sbarro Institute for Cancer Research and Molecular Medicine, Temple University, Philadelphia, USA.

Davide Campagna (D)

Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.

Agostino Di Ciaula (A)

Clinica Medica "A. Murri" Department of Precision and Regenerative Medicine and Ionian Area [DiMePre-J], University "Aldo Moro" Medical School, Bari, Italy.

Tabinda Dugal (T)

Department of Endocrinology College of Physicians and Surgeons, Royal Cornwall Hospital NHS Trust, Truro, UK.

Andre Kengne (A)

Non-Communicable Diseases Research Unit, South African Medical Research Council and University of Cape Town, Cape Town, South Africa; Department of Biological and Environmental Science, Faculty of Science, Walter Sisulu University, Mthatha, South Africa.

Phuong Le Dinh (P)

General Practice, Family Medicine and Check-up Department, FV Hospital Ho Chi Minh City, Viet Nam.

Anoop Misra (A)

Diabetes Foundation [India], New Delhi, India; National Diabetes, Obesity and Cholesterol Foundation [N-DOC], New Delhi, India; Fortis C-DOC Centre for Excellence for Diabetes, Metabolic Disease, and Endocrinology, New Delhi, India.

Riccardo Polosa (R)

Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy; Center of Excellence for the acceleration of Harm Reduction [CoEHAR], University of Catania, Vietnam, Italy; Centre for the Prevention and Treatment of Tobacco Addiction (CPCT), University Teaching Hospital "Policlinico-Vittorio Emanuele", University of Catania, Catania, Italy.

Syed Abbas Raza (SA)

Shaukat Khanum Cancer Hospital and Research Center, Peshawar, Pakistan.

Cristina Russo (C)

Ashford and Saint Peter's Hospitals NHS Foundation Trust, Chertsey, UK.

Roberta Sammut (R)

Department of Nursing, Faculty of Health Sciences, University of Malta, Msida, Malta.

Noel Somasundaram (N)

Diabetes and Hormone Center, Colombo, Sri Lanka.

Classifications MeSH